BiopharmaTrend.com

Aqemia

Aqemia

Private company
AQEMIA
Paris

Aqemia is an in silico drug discovery start-up, whose ambition is to discover rapidly more innovative therapeutic molecules with better chances of success.

How? Just like an AI can learn to play chess, Aqemia’s generative AI learns to invent relevant compounds thanks to unique Statistical Mechanics algorithms predicting drug-target affinity among other properties. Aqemia differentiation lies in its affinity prediction both accurate and 10 000x faster than competition, enabling efficient guidance of generation towards compounds with better chances to become drugs.

Aqemia is a spin-off of École Normale Supérieure leveraging disruptive Quantum-inspired Statistical Mechanics algorithms from 8 years of research. Aqemia’s team is composed of high profiles at the crossroads of Medicinal Chemistry, Statistical Mechanics and Artificial Intelligence.


Founded
2019
Status
Private company
Geography
France based
Funding
$1.800 M
Machine Learning Quantum AI Artificial Intelligence drug discovery in silico drug design Structure-based Statistical Mechanics

Products

No products posted yet

Services

Lead generation as a service
in silico drug design machine learnin

Maximilien Levesque
Founder
 
Emmanuelle Martiano
Founder
 

This data is part of our proprietary analytics report:

This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality

Go to home page